Description, This document provides guidance on the content and qualification of impurities in new drug products for registration applications. This ICH guideline (draft) provides recommendations for the limits and the qualification of impurities to be observed for the marketing authorization of medicinal. ICH Q3B(R) C. Impurities in New Drug Products ICH Q3AR. 1. Introduction. Objective of the Guideline. Guidance for registration or marketing application .

Author: Tosida Sataur
Country: Finland
Language: English (Spanish)
Genre: Marketing
Published (Last): 20 February 2006
Pages: 497
PDF File Size: 13.50 Mb
ePub File Size: 17.33 Mb
ISBN: 465-6-67991-962-3
Downloads: 67588
Price: Free* [*Free Regsitration Required]
Uploader: Nikogore

The situation with impurities potentially needing qualification also underscores the importance of completing a thorough bioanalytical assessment of each drug substance lot to identify the impurities gyidelines and their relative concentration.

Drug substance and drug product impurities, now what?

What do we do now? The thresholds are broadly dependent on the daily quantity of drug consumed by the patient with threshold tolerances being lower when the maximum exposure is greater than 2 grams of drug substance per day. The qualification threshold is the level at which the impurity in the drug product must be qualified for safety.

This approach could potentially save precious time at the latter stages of drug development. Toxicological overview of impurities in pharmaceutical products. When there are 3 or more class 2 or 3 impurities, the total of all mutagenic impurities should be per the values provided Source: An unidentified peak in a drug substance or drug product chromatogram raises many questions. These classes range from known mutagenic carcinogens Class 1 to compounds with no structural alerts or with sufficient data to demonstrate lack of mutagenic or carcinogenic potential Class 5.

The identification threshold is the level at which an impurity must be structurally identified. Since impurities in the drug substance may not be related to or derived from the drug substance, the impuriites may be more toxic than impurities in the drug product which are related to the active drug substance by definition.

As per the ICH Q3A R2 1 guideline, impurities in the drug substance below the qualification threshold levels do not need to be qualified unless the impurity is expected to be unusually toxic or potent Table 1. Insights regarding acceptable amounts of residual solvents and the calculation of permitted daily exposures will be the subject of another review. February 27, Correspondence: Qualification may include genotoxicity assessments based on QSAR assessments and scientific published literature; in some cases more extensive genetic toxicity testing may be required.

While a thorough bioanalytical assessment of impurities in early drug lots is rare, sponsors should consider devoting resources to these efforts up-front to have this potentially critical information available. Drug product impurities are defined as, and limited to, degradation products of the drug substance, and reaction products of the drug substance with excipients or the container-closure system. Information in the FDA 5 summary basis of approval cannot be used for this purpose.


February 21, Published: Other types of genotoxicants that are non-mutagenic typically have threshold mechanisms eg, endocrine active substances and usually do not pose carcinogenic risk in humans at the level ordinarily present as impurities. Since body guidelined area varies with body weight W 0. The battery of nonclinical studies typically required for qualification include two genetic toxicology studies the bacterial reverse mutation [Ames] assay and a chromosomal damage [i.

Sponsors are also reminded to use allometric scaling to compare impurity exposures in nonclinical ichh with impurity exposures in humans. However, for the toxicologist the issue for any impurity that exceeds qualification thresholds is whether sufficient safety information exists, either in completed nonclinical or clinical studies or in the literature, to support continued development or whether the impurity needs to be qualified through the conduct of additional safety studies.

Toxicology studies to establish safety should compare the new drug substance or drug product containing a representative amount of the new impurity with previously qualified test article or using the isolated impurity only. Impurities in drug substances may include starting materials, intermediates, degradation products, etc.

The reporting threshold is the level at which an impurity must be reported with the analytical procedures indicated.

The km value for each species increases with body weight, but a fixed k m factor for each species is preferred for standardization and practical purposes. If the impurity is from a class of compounds known to be particularly toxic or nontoxic, the qualification thresholds may be lowered or raised, respectively. Table 1 presents the drug substance impurity thresholds described in ICH Q3A R2 1 which trigger reporting, identification, and qualification requirements.

The correction factor k m is estimated by dividing the average body weight kg for the species by that species body surface area m 2. Drug substance impurities and drug product impurities are not the same, and are subject to different regulatory requirements. If neither option is feasible, empirical toxicology testing will have to be performed to qualify the impurity. FDA Guidance for Industry: Edmond, OK Tel: In drug substance purity testing, every peak that appears in the chromatogram should be considered a drug substance impurity, unless proven otherwise eg, solvent peaks.

This dose-by-factor strategy is based on minimum risk of toxicity rather than minimum pharmacologic activity. Given the apparent increased scrutiny regarding impurities, toxicology programs for molecules early in development should consider using a well-characterized drug substance of lower purity. Drug substance and drug product impurities, now what? The most accurate predictions occur for renally excreted compounds with low hepatic metabolism and a low volume of distribution.


ICH Q3B(R2) Impurities in New Drug Products

If the daily intake of an impurity is above the acceptable intake levels, the impurity should be identified and a stepwise approach can be taken for qualification.

Impurities in the guudelines substance primarily originate during the synthetic process using raw materials, intermediates, and by-products present in the reaction mixture at much lower purity requirements than for the drug substance.

For species not listed or for weights outside the standard ranges, HED can be calculated from the following formula: In some cases, it may be simpler to decrease impurity levels to no more than the threshold rather than conducting safety studies.

This practice increases the chances that any potential impurity will be present in the drug substance and thus considered qualified in that study when the drug substance impurity is present at multiples higher than the clinical exposure.

ICH Q3B (R2) Impurities in new drug products | European Medicines Agency

Drug substance and drug product impurities are a current hot button issue with regulatory authorities.

No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use. Qualification of drug substance and drug product impurities are broadly dependent on the maximum theoretical clinical dose, whereas potential mutagenic impurities must be controlled to levels less than the threshold of toxicological concern based on lifetime exposure.

This is an open access article distributed under the terms of the Creative Commons Attribution Licensewhich permits unrestricted use, distribution, and build upon your work non-commercially. Click here to submit your manuscript Ideally, mutagenic impurities should be eliminated by modification of the formulation, synthetic route, starting materials, reactants, or through additional purification.

The decision tree for the identification and qualification of drug product impurities see Attachment 3 in the ICH Q3B R2 2 guideline should be closely followed and thoroughly discussed with the regulatory authority to resolve drug product impurity issues. Drug substance impurities Table 1 presents the drug substance impurity thresholds described in ICH Q3A R2 1 which trigger reporting, guidelies, and qualification requirements.

Based on a work at https: